Studies Linking Use of Xarelto to Excessive Bleeding Support Xarelto Lawsuit Plaintiffs In Their Cases Against the Manufacturers of the Drug

September 10, 2016 – – TheProductLawyers.com reports on lawsuits that are underway against the manufacturers of Xarelto, with 550 cases in a mass tort group in Philadelphia, PA along with an additional 2,800 cases in a multidistrict litigation (number 2592) in Louisiana consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPMDL) and overseen by the Honorable Judge Eldon Fallon.

Xarelto was approved by the U.S. Food and Drug Administration (FDA) in 2011 to treat patients who were at an increased risk of stroke or blood clots due to various medical conditions or recovering from surgical procedures. Patients suffering from deep vein thrombosis, pulmonary embolism or atrial fibrillation or those who required hip or knee replacement surgery were likely to receive the blood-thinning drug Xarelto. As a new-generation blood thinner drug, it was met with a lot of excitement upon its release on the market. However, it was not long after its release that patients began to experience potentially life-threatening side effects related to dangerous and sudden instances of uncontrollable bleeding which they linked to use of the drug.

Patients have used a number of studies that have been conducted on these various side effects to support their cases in court. One such study was done by two doctors of their own prompting. Judy Hun and John Hwang began to notice that many of their patients taking Xarelto began to suffer from episodes of eye bleeding, otherwise known as “spontaneous vitreous hemorrhage.” After their own investigation, they concluded that the risk of eye bleeds could be increased in those patients taking Xarelto.

Another study conducted over the course of almost two years beginning on October 1, 2010 and concluding on March 31, 2012, evaluated the potential linkage of excessive bleeding to Xarelto. The study evaluated almost 46,000 users of blood-thinning drugs such as warfarin, Pradaxa and Xarelto. The primary conclusion was that the use of Xarelto produced much higher levels of uncontrollable bleeding than the other blood-thinning drugs included in the study.

If you have any questions, or if would like more information about Xarelto bleeding lawsuits, please contact Laurence Banville, Esq. by calling 888-478-9711.

###

Contact TheProductLawyers.com:

Banville Law
888-478-9711
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60012134